Highly effective blue-chip pharmaceutical regulatory affairs leader, operating at Vice President and above level since June 2012. I have extensive experience leading regulatory affairs departments in vaccines, hematology, and oncology therapeutic areas.Currently, I lead in the field of vaccines regulatory affairs and public health, overseeing a substantial portfolio of vaccines in various stages of development and utilizing different technologies.My experience at CEPI has enabled me to develop and engage with a significant network of contacts in regulatory authorities across high, middle, and low-income countries. I continue to have extensive first-hand engagements with regulators, discussing product development strategies and regulatory innovations to accelerate vaccine development in preparation for future outbreaks.My career has been driven by increasingly strategic roles, with expertise spanning a diverse range of departments and therapeutic areas. I have worked with innovative technologies and product classes in both regional and global roles.I excel in driving Quality and Compliance strategies by providing oversight and leadership to manufacturing and R&D organizations.In parallel to my existing role at CEPI, I was appointed as Chair of the Review Panel (MHRA) in January 2024, where I am accountable for statutory and non-statutory reviews of proposals, decisions, and provisional decisions taken by the MHRA.I am also an experienced public speaker, panellist, chair, and moderator at numerous scientific meetings and conferences